Nuformix (NFX) Competitors

GBX 0.17
-0.01 (-6.49%)
(As of 06:26 AM ET)

NFX vs. PYC, OVB, FAB, APTA, EVG, OCTP, IXI, VAL, BSFA, and ROQ

Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Physiomics (PYC), Ovoca Bio (OVB), Fusion Antibodies (FAB), Aptamer Group (APTA), Evgen Pharma (EVG), Oxford Cannabinoid Technologies (OCTP), IXICO (IXI), ValiRx (VAL), BSF Enterprise (BSFA), and Roquefort Therapeutics (ROQ). These companies are all part of the "biotechnology" industry.

Nuformix vs.

Nuformix (LON:NFX) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.

Physiomics has higher revenue and earnings than Nuformix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuformix£50K28.35-£1.20MN/AN/A
Physiomics£900.71K1.68N/AN/AN/A

0.2% of Nuformix shares are held by institutional investors. Comparatively, 0.1% of Physiomics shares are held by institutional investors. 15.0% of Nuformix shares are held by company insiders. Comparatively, 6.3% of Physiomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nuformix has a net margin of 0.00% compared to Physiomics' net margin of -70.32%. Nuformix's return on equity of -27.25% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -27.25% -17.20%
Physiomics -70.32%-62.94%-37.22%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuformix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Physiomics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Physiomics received 12 more outperform votes than Nuformix when rated by MarketBeat users. However, 66.67% of users gave Nuformix an outperform vote while only 55.56% of users gave Physiomics an outperform vote.

CompanyUnderperformOutperform
NuformixOutperform Votes
68
66.67%
Underperform Votes
34
33.33%
PhysiomicsOutperform Votes
80
55.56%
Underperform Votes
64
44.44%

Nuformix has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Physiomics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Physiomics'average media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Physiomics Neutral

Summary

Nuformix beats Physiomics on 8 of the 11 factors compared between the two stocks.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

MetricNuformixBiotechnology IndustryMedical SectorLON Exchange
Market Cap£1.42M£165.77M£5.03B£1.43B
Dividend YieldN/A3.43%36.92%11.85%
P/E Ratio-1.63250.62122.651,670.54
Price / Sales28.3515,816.582,487.66290,017.27
Price / Cash3.5511.3435.6232.85
Price / Book0.176.315.492.71
Net Income-£1.20M-£15.03M£104.58M£174.96M
7 Day Performance-6.49%0.69%0.64%0.89%
1 Month Performance-19.16%5.02%2.08%7.38%
1 Year Performance-25.75%3.79%5.35%8.46%

Nuformix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYC
Physiomics
0 of 5 stars
GBX 1.35
+3.8%
N/A-60.4%£1.83M£900,707.00-13.8310Gap Up
OVB
Ovoca Bio
0 of 5 stars
GBX 0.75
flat
N/A-87.8%£612,000.00N/A-37.505
FAB
Fusion Antibodies
0 of 5 stars
GBX 3.40
+1.5%
N/A-90.9%£3.24M£1.58M-37.7848Gap Down
APTA
Aptamer Group
0 of 5 stars
GBX 0.70
+2.9%
N/A-93.0%£3.27M£1.03M-8.7537Gap Down
EVG
Evgen Pharma
0 of 5 stars
GBX 0.80
flat
N/A-79.5%£3.42MN/A-80.0010
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.35
+2.9%
N/A-89.3%£3.82MN/A-53.107Gap Up
IXI
IXICO
0 of 5 stars
GBX 8.13
flat
N/A-62.2%£3.93M£6.67M-406.2589
VAL
ValiRx
0 of 5 stars
GBX 3.30
+1.5%
N/A-69.5%£4.37MN/A-110.008News Coverage
BSFA
BSF Enterprise
0 of 5 stars
GBX 5
flat
N/A-65.7%£5.17MN/A-250.0012Gap Up
ROQ
Roquefort Therapeutics
0 of 5 stars
GBX 4.55
+3.4%
N/AN/A£5.88M£637.00-455.009Gap Down

Related Companies and Tools

This page (LON:NFX) was last updated on 5/15/2024 by MarketBeat.com Staff

From Our Partners